Shares of other companies:
April 29, 2024 Tesla, Baidu Join Forces for Self-Driving Tech in China
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Facing A Liquidity Crunch; Dilution Ahead?
April 29, 2024
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
CTLT Stock News and Mentions of Catalent, Inc. Stocktwits
Updated: April 29, 2024 (10:08)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Catalent Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Catalent, Inc. (CTLT).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Catalent stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Catalent, Inc. (CTLT)
April 29, 2024 (17:33) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in Novo Nordisk ( NVO ) Ahead of Q1 Earnings?
Novo Nordisk's (NVO) revenues in the first quarter of 2024 are expected to have been driven by its diabetes and obesity care product sales, especially Ozempic, Rybelsus and Wegovy.
In Article Trend: Somewhat-Bullish
April 27, 2024 (06:24) / "Stocknews.com" (by Defense World Staff)
Catalent ( NYSE:CTLT ) Now Covered by StockNews.com
Investment analysts at StockNews.com initiated coverage on shares of Catalent ( NYSE:CTLT - Get Free Report ) in a report released on Saturday. The firm set a "sell" rating on the stock. CTLT has been the topic of several other reports.
In Article Trend: Somewhat-Bullish
April 26, 2024 (20:19) / "Benzinga" (by Globe Newswire)
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - CTLT, MGRC, CHRD, HRT
NEW YORK, April 26, 2024 ( GLOBE NEWSWIRE ) -- Monteverde & Associates PC ( the "M&A Class Action Firm" ) , has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.
In Article Trend: Somewhat-Bullish
April 26, 2024 (12:56) / "Benzinga" (by Globe Newswire)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HCP, NXPL, CTLT - HashiCorp ( NASDAQ:HCP ) , Catalent ( NYSE:CTLT )
NEW YORK, April 26, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: HashiCorp Inc.
In Article Trend: Somewhat-Bullish
April 25, 2024 (15:40) / "Zacks Commentary" (by Zacks Equity Research)
TAK or CTLT: Which Is the Better Value Stock Right Now?
TAK vs. CTLT: Which Stock Is the Better Value Option?
In Article Trend: Bullish
April 25, 2024 (12:33) / "Zacks Commentary" (by Zacks Equity Research)
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.
In Article Trend: Somewhat-Bullish
April 24, 2024 (18:15) / "Motley Fool" (by Motley Fool Transcribing)
Thermo Fisher Scientific ( TMO ) Q1 2024 Earnings Call Transcript
TMO earnings call for the period ending March 31, 2024.
In Article Trend: Somewhat-Bullish
April 24, 2024 (14:09) / "Zacks Commentary" (by Kinjel Shah)
4 Large Drug Stocks to Hold on to Amid Industry Challenges
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
In Article Trend: Somewhat-Bullish
April 19, 2024 (08:05) / "Stocknews.com" (by Defense World Staff)
Catalent ( NYSE:CTLT ) Coverage Initiated by Analysts at StockNews.com
Equities research analysts at StockNews.com assumed coverage on shares of Catalent ( NYSE:CTLT - Get Free Report ) in a research report issued on Friday. The brokerage set a "sell" rating on the stock. Other research analysts have also issued research reports about the company.
In Article Trend: Somewhat-Bullish
April 13, 2024 (15:16) / "Investors Business Daily" (by Investor's Business Daily)
Nvidia Leads 5 Stocks Near Buy Points
Nvidia ( NVDA ) and uranium producer Cameco ( CCJ ) lead this weekend's watch list of five stocks near buy points. Both NVDA and CCJ bucked the trend over the past week as the S&P 500 slipped back to its 50-day moving average for the first time since early November.
In Article Trend: Neutral
April 12, 2024 (17:22) / "Benzinga" (by Vandana Singh)
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating - Novo Nordisk ( NYSE:NVO )
BMO Capital Markets initiated coverage on Danish drug maker Novo Nordisk A/S NVO after the company garnered interest as it hit the holy grail with the next generation of famed weight loss and diabetes drugs.
In Article Trend: Bullish
April 12, 2024 (10:30) / "Forbes" (by Giacomo Tognini)
Meet The Billionaire-Owned Company Making Injectors For Blockbuster Drugs Like Ozempic
Billionaire-Owned SHL Medical Makes Injectors For Drugs Like Ozempic Forbes ...
In Article Trend: Neutral
April 11, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
Charles River ( CRL ) Forges Collaboration With Ship of Theseus
Charles River (CRL) is set to perform plasmid production for Ship of Theseus.
In Article Trend: Somewhat-Bullish
April 11, 2024 (06:18) / "Stocknews.com" (by Defense World Staff)
StockNews.com Begins Coverage on Catalent ( NYSE:CTLT )
StockNews.com started coverage on shares of Catalent ( NYSE:CTLT - Get Free Report ) in a report released on Thursday. The brokerage set a "sell" rating on the stock.
In Article Trend: Somewhat-Bullish
April 11, 2024 (03:03) / "Benzinga" (by Globe Newswire)
Robbins LLP is Investigating the Acquisition of Catalent, Inc. ( CTLT ) by Novo Holdings - Catalent ( NYSE:CTLT )
SAN DIEGO, April 10, 2024 ( GLOBE NEWSWIRE ) -- Shareholder rights law firm Robbins LLP informs investors it is investigating the acquisition of Catalent, Inc. CTLT by Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk ...
In Article Trend: Somewhat-Bullish
April 10, 2024 (10:45) / "Motley Fool" (by David Jagielski)
Novo Nordisk's Stock Could Get Another Boost, Thanks to This Huge Development
It may not be too late to invest in this promising healthcare stock, even though it may look expensive.
In Article Trend: Somewhat-Bullish
April 5, 2024 (16:35) / "Investors Business Daily" (by ALLISON GATLIN)
Why A Pullback Is Bullish For IBD Stock Of The Day Novo Nordisk
Novo Nordisk ( NVO ) is Friday's IBD Stock Of The Day. After hitting a record high in March, shares have pulled back amid new developments in the weight-loss drugs frenzy. Last month, Novo said its next-generation weight-loss pill, amycretin, outperformed blockbuster Wegovy in an early-stage ...
In Article Trend: Somewhat-Bullish
April 4, 2024 (15:16) / "Benzinga" (by Globe Newswire)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLT, SCX, EVBG, NS - Catalent ( NYSE:CTLT ) , Everbridge ( NASDAQ:EVBG )
NEW YORK, April 04, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Catalent, Inc.
In Article Trend: Somewhat-Bullish
April 4, 2024 (14:53) / "Benzinga" (by Globe Newswire)
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - NS, CTLT, SCX, EVBG
NEW YORK, April 04, 2024 ( GLOBE NEWSWIRE ) -- Monteverde & Associates PC ( the "M&A Class Action Firm" ) , has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.
In Article Trend: Somewhat-Bullish
April 4, 2024 (11:30) / "Motley Fool" (by Adam Spatacco)
After Wegovy's Approval to Treat Heart Disease, Novo Nordisk Continues to Make Moves
Novo Nordisk is off to a red-hot start in 2024, and its latest deal could represent huge potential.
In Article Trend: Bullish
April 3, 2024 (20:07) / "Benzinga" (by Neil Dennis)
Eli Lilly Struggles To Keep Pace With Mounjaro, Zepbound Demand: 'Currently Unavailable' On Amazon Pharmacy - Eli Lilly and Co ( NYSE:LLY ) , Amazon.com ( NASDAQ:AMZN )
After a blistering performance based on the success of its weight-loss treatments Mounjaro and Zepbound, Eli Lilly & Company LLY stock has been trading sideways for the last five weeks as the company struggles to keep pace with demand for the drugs.
In Article Trend: Neutral
April 3, 2024 (06:12) / "Stocknews.com" (by Defense World Staff)
Catalent ( NYSE:CTLT ) Coverage Initiated at StockNews.com
Analysts at StockNews.com started coverage on shares of Catalent ( NYSE:CTLT - Get Free Report ) in a research note issued on Wednesday. The firm set a "sell" rating on the stock.
In Article Trend: Somewhat-Bullish
March 31, 2024 (22:14) / "Motley Fool" (by David Jagielski)
Is Novo Nordisk the Best Healthcare Stock for You?
Novo Nordisk has been a hot buy in recent years, but in the long run, the stock can still go a whole lot higher.
In Article Trend: Somewhat-Bullish
March 26, 2024 (09:51) / "Motley Fool" (by Keith Speights)
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
All three of these high-flying stocks could have more room to run.
In Article Trend: Somewhat-Bullish
March 26, 2024 (06:42) / "Stocknews.com" (by Defense World Staff)
Catalent ( NYSE:CTLT ) Coverage Initiated at StockNews.com
Equities researchers at StockNews.com started coverage on shares of Catalent ( NYSE:CTLT - Get Free Report ) in a report released on Tuesday. The firm set a "sell" rating on the stock.
In Article Trend: Somewhat-Bullish
March 22, 2024 (22:59) / "PR Newswire" (by Halper Sadeh LLP)
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CTLT, HRT, NGM, SDPI
NEW YORK, March 22, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: sale to Novo Holdings for $63.50 per share in ...
In Article Trend: Somewhat-Bullish
March 22, 2024 (18:15) / "PR Newswire" (by Research and Markets)
Global Contract Development and Manufacturing Organization Research Report 2024: Vendors are Anticipated to Concentrate on Offering One-Stop-Shop Services to Gain a Competitive Edge - Forecast to 2029
Global Contract Development and Manufacturing Organization Research Report 2024: Vendors are Anticipated to ... PR ...
In Article Trend: Somewhat-Bullish
March 22, 2024 (17:34) / "Benzinga" (by Globe Newswire)
Kuehn Law Encourages NGM, CTLT, SDPI, and HRT Investors to Contact Law Firm - Catalent ( NYSE:CTLT ) , HireRight Holdings ( NYSE:HRT )
NEW YORK, March 22, 2024 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.
In Article Trend: Bullish
March 22, 2024 (11:15) / "Motley Fool" (by Adam Spatacco)
Did Eli Lilly Just One-Up Novo Nordisk?
Eli Lilly just partnered with Amazon to help accelerate distribution of its various treatments.
In Article Trend: Bullish
March 21, 2024 (16:04) / "Benzinga" (by Globe Newswire)
Global Pharmaceutical Supply Chain Management Market Report 2024 Highlights Strong Growth and Technological Advancements: Market Size to Reach $ 3.63 Billion in 2028
LONDON, March 21, 2024 ( GLOBE NEWSWIRE ) -- The global market for pharmaceutical supply chain management has seen significant growth in recent years, as indicated by the latest report titled " Pharmaceutical Supply Chain Management Global Market Report 2024" from The Business Research Company.
In Article Trend: Somewhat-Bullish
March 19, 2024 (14:00) / "Motley Fool" (by Adam Spatacco)
Is Novo Nordisk on the Verge of Another Blockbuster Drug?
Novo Nordisk just received some positive news for its latest obesity drug, amycretin.
In Article Trend: Somewhat-Bullish
March 19, 2024 (11:30) / "Motley Fool" (by Adam Spatacco)
Did Novo Nordisk Just Get a Jump on Eli Lilly?
A recent FDA announcement may have just put one company in the lead.
In Article Trend: Somewhat-Bullish
March 18, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Is Invesco S&P 500 Equal Weight Health Care ETF ( RSPH ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
March 18, 2024 (06:28) / "Stocknews.com" (by Defense World Staff)
StockNews.com Begins Coverage on Catalent ( NYSE:CTLT )
Analysts at StockNews.com began coverage on shares of Catalent ( NYSE:CTLT - Get Free Report ) in a note issued to investors on Monday. The brokerage set a "sell" rating on the stock. A number of other equities analysts also recently issued reports on the stock.
In Article Trend: Somewhat-Bullish
March 13, 2024 (12:30) / "Benzinga" (by Globe Newswire)
Global In Vitro Toxicology Testing Market Size is projected to reach USD 28.19 billion by 2031, growing at a CAGR of 10.8%: Straits Research
New York, United States, March 13, 2024 ( GLOBE NEWSWIRE ) -- In Vitro toxicology testing is used to determine the toxicity of a substance on non-living cells or tissues. It is a crucial component of preclinical safety evaluation in the pharmaceutical, chemical, and regulatory industries.
In Article Trend: Somewhat-Bullish
March 12, 2024 (14:30) / "PR Newswire" (by Cellipont Bioservices)
Cellipont Bioservices Appoints Edwin Beale as Chief Commercial Officer
THE WOODLANDS, Texas, March 12, 2024 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization ( CDMO ) , today announced the appointment of Edwin Beale as its new Chief Commercial Officer, effective immediately.
In Article Trend: Bullish
March 12, 2024 (00:22) / "PR Newswire" (by Pomerantz LLP)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT
NEW YORK, March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. ( "Catalent" or the "Company" ) ( NYSE: CTLT ) . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
In Article Trend: Neutral
March 10, 2024 (07:12) / "Stocknews.com" (by Defense World Staff)
Catalent ( NYSE:CTLT ) Now Covered by Analysts at StockNews.com
StockNews.com started coverage on shares of Catalent ( NYSE:CTLT - Get Free Report ) in a note issued to investors on Sunday. The firm set a "sell" rating on the stock. CTLT has been the subject of a number of other research reports.
In Article Trend: Somewhat-Bullish
March 8, 2024 (16:12) / "Benzinga" (by Vandana Singh)
Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug - Novo Nordisk ( NYSE:NVO )
Novo Nordisk A/S's NVO head of development, Martin Holst Lange, expressed strong confidence in the drugmaker's ability to launch the pill version of its experimental weight loss drug, amycretin, within this decade. The optimism follows the announcement of robust early trial data.
In Article Trend: Somewhat-Bullish
March 7, 2024 (21:55) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT - Catalent ( NYSE:CTLT )
NEW YORK, March 07, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. ( "Catalent" or the "Company" ) CTLT. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
In Article Trend: Neutral
March 7, 2024 (13:00) / "Investors Business Daily" (by Investor's Business Daily)
8 Stocks Already Up Big This Year Will Rise Even More, Analysts
Missed big runs in some S&P 500 stocks? Don't worry - it's not too late. Analysts found rising stocks with plenty of more upside.
In Article Trend: Somewhat-Bullish
March 7, 2024 (12:40) / "Benzinga" (by Globe Newswire)
Global Softgel Capsules Market Size is Estimated to Reach USD 14.86 billion by 2030, Growing at a CAGR of 7.81%: Straits Research
New York, United States, March 07, 2024 ( GLOBE NEWSWIRE ) -- Softgel capsules dissolve more quickly in gastric fluids than a hard gelatin capsules because they contain liquid, semisolid, or solid medication.
In Article Trend: Somewhat-Bullish
March 7, 2024 (11:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF ( RSPH ) ?
Sector ETF report for ...
In Article Trend: Somewhat-Bullish
March 6, 2024 (14:33) / "Benzinga" (by Vandana Singh)
What's Going With Eli Lilly Stock On Wednesday? - Eli Lilly and Co ( NYSE:LLY )
Eli Lilly LLY is aggressively pursuing collaborations with outsourcing partners to ramp up the production of its obesity drug, Zepbound ( tirzepatide ) , as it inks deals with key players such as National Resilience and BSP Pharmaceuticals for the filling and "finishing" of its injector pens.
In Article Trend: Neutral
March 5, 2024 (14:53) / "Motley Fool" (by Adam Spatacco)
Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why
Eli Lilly and Novo Nordisk dominate the diabetes market thanks to blockbuster medications Mounjaro, Ozempic, and Rybelsus.
In Article Trend: Somewhat-Bullish
March 4, 2024 (21:03) / "The Economist" (by The Economist)
The battle over the trillion-dollar weight-loss bonanza
W drugs called -1 agonists help users shed fat, and with it the negative health effects of obesity. This can have life-changing effects for the people who take them. It is also increasingly affecting the lives of corporate citizens.
In Article Trend: Neutral
March 2, 2024 (07:51) / "Stocknews.com" (by ABMN Staff)
StockNews.com Initiates Coverage on Catalent ( NYSE:CTLT )
StockNews.com Initiates Coverage on ...
In Article Trend: Somewhat-Bullish
March 2, 2024 (07:50) / "Stocknews.com" (by Defense World Staff)
StockNews.com Initiates Coverage on Catalent ( NYSE:CTLT )
Equities researchers at StockNews.com started coverage on shares of Catalent ( NYSE:CTLT - Get Free Report ) in a note issued to investors on Saturday. The brokerage set a "sell" rating on the stock. Other equities analysts have also issued research reports about the stock.
In Article Trend: Somewhat-Bullish
March 2, 2024 (00:48) / "PR Newswire"
Biopharmaceutical Analytical Testing Services Market size to grow by USD 3.45 billion from 2022 to 2027, North ... - PR Newswire
Biopharmaceutical Analytical Testing Services Market size to grow by USD 3.45 billion from 2022 to 2027, North ... PR ...
In Article Trend: Somewhat-Bullish
March 1, 2024 (22:02) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Agiliti Inc. by Thomas H. Lee Partners, L.P. - Agiliti ( NYSE:AGTI )
NEW YORK, March 01, 2024 ( GLOBE NEWSWIRE ) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Agiliti Inc. ( "Agiliti" or the "Company" ) AGTI stock purchased prior to February 26, 2024.
In Article Trend: Neutral
March 1, 2024 (21:57) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Catalent, Inc. by Novo Holdings - Catalent ( NYSE:CTLT )
NEW YORK, March 01, 2024 ( GLOBE NEWSWIRE ) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Catalent, Inc. ( "Catalent" or the "Company" ) CTLT stock purchased prior to February 16, 2024.
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website